- Home
- OSTX
OSTX
OS THERAPIES INCORPORATED
as 04-18-2025 1:41pm EST
Stocks
| Founded: | 2018 | Country: | United States |
| Employees: | N/A | City: | ROCKVILLE |
| Market Cap: | N/A | IPO Year: | 2024 |
| Target Price: | $18.00 | AVG Volume (30 days): | 150.1K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 3 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.88 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.12 - $7.00 | Next Earning Date: | 05-15-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest OS THERAPIES INCORPORATED News
OSTX Breaking Stock News: Dive into OSTX Ticker-Specific Updates for Smart Investing
Business Wire
9 days ago
OS Therapies Announces Positive Data for OST-HER2 in the Treatment of Unresected Osteosarcoma in Dogs Opening the Potential for Use as Front-Line Therapy in Humans
MT Newswires
10 days ago
OS Therapies Finalizes Acquisition of Advaxis Assets From Ayala Pharmaceuticals
Business Wire
10 days ago
OS Therapies Completes Acquisition of Advaxis Immunotherapies Clinical, Pre-clinical and IP Assets from Ayala Pharmaceuticals
Business Wire
12 days ago
OS Therapies Requests Meeting with FDA to Gain Agreement on Surrogate Endpoint(s) for Breakthrough Therapy Designation & Accelerated Approval of OST-HER2 in the Prevention of Recurrence of Fully Resected, Lung Metastatic Osteosarcoma
Business Wire
17 days ago
OS Therapies to Host Analyst Day at NYSE on April 7, 2025
Business Wire
19 days ago
OS Therapies Reports Full Year 2024 Financial Results and Provides Business Update
Business Wire
19 days ago
OS Therapies Provides Regulatory Update on Rare Pediatric Cancer Immunotherapy Candidate OST-HER2 for Human Osteosarcoma
Business Wire
25 days ago
OS Therapies’ OST-HER2 Immunotherapy for Osteosarcoma Featured in Upcoming Movie Shelter Me: The Cancer Pioneers
Compare OSTX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "OSTX OS THERAPIES INCORPORATED - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.